Sight Sciences, Inc. (SGHT) Bundle
A Brief History of Sight Sciences, Inc. (SGHT)
Company Overview
Sight Sciences, Inc. is a medical technology company focused on developing innovative ophthalmic devices for treating eye diseases.
Financial Performance
| Fiscal Year | Revenue | Net Income | Stock Price (as of Q4 2023) |
|---|---|---|---|
| 2022 | $81.4 million | -$57.3 million | $3.82 |
| 2023 | $103.2 million | -$42.6 million | $5.15 |
Key Products
- OMNI Surgical System
- TRIDENT Hydrus Microstent
- TEAR Osmolarity Test
Market Presence
Publicly traded on NASDAQ since October 2021 with initial public offering price of $16 per share.
Operational Metrics
| Metric | 2023 Data |
|---|---|
| Total Employees | 337 |
| Research & Development Expenses | $37.8 million |
| Gross Margin | 79.4% |
Geographical Expansion
- Primary Market: United States
- Emerging Markets: Europe, Asia-Pacific
A Who Owns Sight Sciences, Inc. (SGHT)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group Inc | 1,702,880 | 11.4% |
| BlackRock Inc | 1,457,405 | 9.8% |
| Orbimed Advisors LLC | 1,243,630 | 8.3% |
| Baker Bros. Advisors LP | 1,125,000 | 7.5% |
Insider Ownership
- Paul Badawi (Co-Founder, Chairman): 1,345,678 shares
- Robert Schneider (CEO): 789,456 shares
- Other Executive Officers: 567,890 shares
Ownership Breakdown
Total Outstanding Shares: 14,932,000
| Ownership Category | Percentage |
|---|---|
| Institutional Investors | 62.3% |
| Insider Ownership | 15.7% |
| Retail Investors | 22% |
Sight Sciences, Inc. (SGHT) Mission Statement
Company Overview
Sight Sciences, Inc. is a medical technology company focused on developing innovative ophthalmic devices for treating eye diseases.
Financial Performance
| Total Revenue (2023) | $178.4 million |
| Net Income (2023) | -$57.3 million |
| Market Capitalization (2024) | $579.2 million |
| Stock Price (February 2024) | $13.47 |
Product Portfolio
- TRVP Procedure Platform
- TRION Glaucoma Treatment System
- TearCare System for Dry Eye Disease
Key Strategic Focus Areas
Primary Treatment Areas:
- Glaucoma Management
- Dry Eye Disease
- Anterior Segment Surgical Solutions
Research and Development Investment
| R&D Expenses (2023) | $64.2 million |
| R&D as Percentage of Revenue | 36% |
Market Presence
Geographic Reach: United States, with expanding international markets
Corporate Metrics
| Number of Employees (2024) | 437 |
| Headquarters Location | Menlo Park, California |
How Sight Sciences, Inc. (SGHT) Works
Company Overview
Sight Sciences, Inc. is a medical technology company focused on developing innovative surgical devices for ophthalmology and glaucoma treatment. The company is headquartered in Menlo Park, California.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $242.1 million |
| Gross Margin | 81.4% |
| Net Loss | $66.3 million |
| Cash and Investments | $308.4 million |
Product Portfolio
- OMNI Surgical System for glaucoma treatment
- TearCare System for dry eye disease
- PRECISION Glaucoma Shunt
Market Segments
Primary Markets:
- Ophthalmology
- Glaucoma treatment
- Dry eye disease management
Operational Metrics
| Metric | 2023 Data |
|---|---|
| Number of Employees | 525 |
| Research and Development Expenses | $94.7 million |
| Sales and Marketing Expenses | $146.3 million |
Stock Performance
| Stock Information | 2024 Value |
|---|---|
| Stock Price (as of January 2024) | $14.37 |
| Market Capitalization | $628 million |
| 52-Week Range | $8.75 - $19.42 |
How Sight Sciences, Inc. (SGHT) Makes Money
Revenue Streams
Sight Sciences, Inc. generates revenue through the sale of medical devices focused on ophthalmology and glaucoma treatment.
| Product Line | Annual Revenue (2023) | Market Segment |
|---|---|---|
| TORIC Surgical Platform | $64.3 million | Glaucoma Treatment |
| TRIAD Surgical Platform | $38.7 million | Ophthalmology Procedures |
Product Portfolio
- TORIC Surgical System for microinvasive glaucoma surgery
- TRIAC Surgical Platform for anterior segment procedures
- OMNI Surgical System for comprehensive glaucoma treatment
Financial Performance
Total revenue for fiscal year 2023: $138.4 million
| Financial Metric | 2023 Value |
|---|---|
| Gross Margin | 77.3% |
| Operating Expenses | $132.6 million |
Market Channels
- Direct sales to ophthalmology clinics
- Distributor networks in United States
- International medical device sales
Sight Sciences, Inc. (SGHT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.